Article

The biosimilar decade: Regulatory milestones and a look ahead

Since the first FDA approval of a biosimilar drug in March of 2015, the market for this category has steadily expanded to include more than 60 different products from dozens of manufacturers. In the following timeline, Cencora presents the key regulatory events that have helped this critical industry gain its footing over the last decade. With continued growth in the biosimilars market, we also look ahead to the factors we believe will be most important to its future success.

See our timeline to discover how a decade of approvals is shaping the future of this market.

* Available in English only.
biosimilar_vials

Biosimilars pipeline report

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market. 
* Available in English only.

Related resources

White paper

Evolving landscape of payer coverage for cell and gene therapies (CGTs): Trends and insights

Webinar

Regulatory Data Initiatives in the EU – What you need to know for 2026

Webinar

Harnessing AI to revolutionize pharmacovigilance signal management

Connect with our team

We are here to support you with innovative solutions to help increase access to these emerging therapies.